Sign In
Buy SPRO
$2.80
-0.0300 (-1.06%)
At Close: Jun 03, 2026
Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript
07:32pm, Tuesday, 12'th Aug 2025
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Esther P. Rajavelu - CEO, CFO, President & Treasurer Shai Biran - Corporate Par
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update
04:01pm, Tuesday, 12'th Aug 2025
CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025
04:05pm, Tuesday, 05'th Aug 2025
CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare
Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results
03:20pm, Wednesday, 11'th Jun 2025
Based on the positive results of the registrational Phase 3 PIVOT-PO study, Tebipenem is expected to be approved under the SPA in mid-2026. Spero will not bear any costs or risks since GSK, as a licen
Squarepoint Ops LLC Buys Shares of 55,051 Spero Therapeutics, Inc. (NASDAQ:SPRO)
03:34am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC bought a new stake in Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal
12:21pm, Thursday, 29'th May 2025
SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
11:24am, Wednesday, 28'th May 2025
GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates
06:10pm, Tuesday, 13'th May 2025
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.24 per share a year ago.
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update
04:01pm, Tuesday, 13'th May 2025
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025
08:00am, Monday, 05'th May 2025
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rar
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
04:01pm, Monday, 28'th Apr 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for r
Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript
08:31pm, Thursday, 27'th Mar 2025
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Shai Biran - Senior Director Investor Relations Esther Rajavelu - Interim Chief
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates
06:20pm, Thursday, 27'th Mar 2025
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $0.96 per share a year ago.
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update
04:01pm, Thursday, 27'th Mar 2025
CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for ra
